Proactive Investors - Run By Investors For Investors

ReNeuron 'very encouraged' by positive retinitis pigmentosa study results

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott after announcing that the first group of patients receiving cell therapy for a blindness-causing disease saw “sustained and further improvement” to their sight.

The data's from a phase IIa study of their human retinal progenitor cell (hRPC) treatment for retinitis pigmentosa.

 
Meet Rockfire Resources PLC, Touchstone Exploration Inc, Mkango Resources Ltd and Salt Lake Potash Ltd at our event, London , 20 June 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use